Hello, and thank you for standing by. My name is Regina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Phibro Animal Health Corporation Fourth Quarter and Fiscal Year 2025 Results Webcast and Conference Call. [Operator Instructions] After the speaker's remarks, there will be a question-and-answer session. [Operator Instructions]. I would now like to turn the conference over to Glenn David, Chief Financial Officer. Please go ahead.

Thank you Regina. Good day, and welcome to the Phibro Animal Health Corporation Earnings Call for our fiscal Fourth Quarter and Full Year ending June 30, 2025. My name is Glenn David, and I'm the Chief Financial Officer of Phibro Animal Health Corporation. . I'm joined on today's call by Jack Bendheim, Phibro's Chairman, President and Chief Executive Officer; Donny Bendheim, Director and Executive Vice President of Corporate Strategy; and Larry Miller, Chief Operating Officer. Today, we will cover financial performance for our fourth quarter and full year 2025 and provide financial guidance for our fiscal year ending June 30, 2026. At the conclusion of our remarks, we will open the line for your questions. I would like to remind you that we are providing a simultaneous webcast of this call on our website, pahc.com. Also, on the Investors section of our website, you will find copies of the earnings press release and annual Form 10-K as well as the transcript and slides discussed and presented on this call. Our remarks today will include forward-looking statements, and actual results could differ materially from those projections. For a list and description of certain factors that could cause results to differ I refer you to the forward-looking statements section in our earnings press release. Our remarks include references to certain financial measures, which were not prepared in accordance with Generally Accepted Accounting Principles or U.S. GAAP. I refer you to the non-GAAP financial information section in our earnings press release for a discussion of these measures. Reconciliations of these non-GAAP financial measures to the most directly comparable U.S. GAAP measures are included in the financial tables that accompany the earnings press release. We present our results on a GAAP basis and on an adjusted basis. Our adjusted results exclude acquisition-related items, unusual, nonoperational or nonrecurring items, including stock-based compensation, Other income expense is separately reported in the consolidated statement of operations, including foreign currency losses, gains, net and income taxes related to pretax income adjustments and unusual or nonrecurring income tax items. Now let me introduce our Chairman, President and Chief Executive Officer, Jack Bendheim, to share his opening remarks. Jack?

Thanks, Glenn, and good morning, everyone. I'm pleased to report another strong quarter and a standout finish to fiscal 2025 for Phibro Animal Health. Our results this quarter reflected continued momentum across the business, led once again by Animal Health, where we saw a 53% sales growth and a 47% increase in adjusted EBITDA. Within Animal Health, our MFA and other portfolio bolstered by the Zoetis MFA integration grew 77% in the fourth quarter. Nutritional Specialities and Vaccines also delivered solid gains of 11% and 21%, respectively. These results underscore the strength of our diversified portfolio and the value we're delivering to customers across geographies and species. Looking at the full year, Animal Health sales rose 36% with adjusted EBITDA up 53%. MFAs and other grew 54%, while Nutritional Specialties and Vaccines increased 9% and 13%, respectively. Our Legacy Animal Health business contributed meaningfully with a 7% growth for the year, once again outpacing the growth of the underlying industry. Beyond Animal Health, we saw continued growth in Mineral Nutrition and Performance Products, both in the quarter and for the full year. Consolidated sales were up 39% in the fourth quarter and 27% for the -- while adjusted EBITDA rose 49% and 65%, respectively. Highlighting the operating leverages we're achieving through disciplined execution. Going to guidance of fiscal year 2026. Outlook reflects continued confidence in non trajectory. We're projecting net sales between $1.425 billion and $1.475 billion. Adjusted EBITDA of $225 million to $235 million and adjusted EPS of $2.52 and $2.70. These targets are granted in the strength of our portfolio and the momentum we've built. They also reflect the tangible impact of our Phibro Forward strategy. We made deliberate investments in scaling operations, strengthening our global footprint and enhancing our innovation pipeline. While it's a long-term initiative, we're already seeing benefits in how we operate and deliver value. I'll now turn it back to Glenn for more detail on our performance and guidance, and I look forward to your questions at the end.

Thanks, Jack. And starting with our Q4 performance on Slide 4. Consolidated net sales for the quarter ended June 30, 2025, were $378.7 million, reflecting an increase of $105.5 million or a 39% increase over the same quarter 1 year ago. The Animal Health segment grew 53%, while Mineral Nutrition grew 3% and Performance Products segment grew by 13%. GAAP net income and diluted EPS increased significantly driven by the successful integration of the new MFA business, increases in demand, improved gross margin due to favorable mix and lower input costs, offset by increased SG&A due to higher employee-related costs. After making our standard adjustments to GAAP results, including acquisition-related items, foreign currency losses and certain one- off items, the fourth quarter adjusted EBITDA increased $16.5 million or 49% versus prior year. Adjusted net income and adjusted diluted EPS both increased 39%, increased gross profit driven by sales growth was partially offset by higher adjusted SG&A and higher adjusted interest expense. Moving to the full year. Consolidated net sales for the year ended June 30, 2025, were $1.296 billion, reflecting an increase of $278.5 million or a 27% increase over the prior year. The Animal Health segment grew 36%, while Mineral Nutrition grew 4% and Performance Products grew by 19%. GAAP net income and diluted EPS increased significantly driven by the successful integration of the new MFA business, the initiative -- initial positive impact on Phibro Forward initiatives and favorable gross profit due to higher product demand in the Animal Health segment, partially offset with increased SG&A due to higher employee-related costs and higher interest expense. After making our standard adjustments to GAAP results including acquisition-related items, foreign currency losses and certain one-off items, full year adjusted EBITDA increased $72.4 million or 65%. Adjusted net income and adjusted diluted EPS,…

[Operator Instructions] Our first question will come from the line of Erin Wright with Morgan Stanley.

Great. What does guidance now assume in terms of the underlying organic growth? And can you speak to some of those key headwinds and tailwinds embedded in your guidance assumptions for 2026?

Sure. Thanks for the question. So in terms of underlying organic growth, -- there are a number of things that are driving the sales performance as we move into fiscal year 2026. Obviously, the full 12 months of a Zoetis versus 8 months is a key driver. But in terms of the underlying growth for the Legacy business, we're essentially assuming what we see more in the long term. We look at our MFA business sort of growing in that flat to low single-digit area. And then we expect accelerated growth or continued higher levels growth in both vaccines and Nutritional Specialties and both of those businesses performed particularly well in fiscal year 2025. We expect them to continue to perform well in fiscal year 2026. However, parts, particularly our vaccine portfolio grew over 13% this year. We do expect that to start to stabilize a little bit, but still provide significant growth as we move into fiscal year '26.

Okay. Great. And then on Phibro Forward, can you quantify anything for us in terms of your expectations there and what's ultimately kind of dropping through in terms of cost saves and what some of the key low-hanging fruit areas are for you there? And then also kind of on the cost side, some of the strategic investments that you're making. Could you expand a little bit on that? Is it more about global expansion efforts? Or is it more focused on innovation, any of that more onetime in nature? Or how should we think about those investments going forward?

Yes. Thanks, Erin. So I'll address the first part of your question, and then I'll let Donny address some of the strategic investments that we're making. In terms of Phibro Forward, we saw contributions from Phibro Forward in fiscal year 2025. And and that helped generate the significant earnings growth that we've seen on top of a lot of the other areas that we talked about as well. We expect that to continue as we move into fiscal year 2026. When you look at the guidance range for EBITDA, for example, it's a growth of anywhere from $40 million to $50 million. And as we look at that, a good part of that growth is coming from the annualization of the Zoetis portfolio, but the remainder comes from contributions to the legacy business and contributions from Phibro Forward as well. The other thing is we look at Phibro Forward, we expect that to peak in fiscal year 2027. So we do expect it to continue to be a driver of growth as we move into fiscal year 2027 as well. I'll let Donny talk about some of these strategic areas of investment.

Yes. Thanks, Erin. So Phibro Forward really is across the entire business. And on the sales side, it involves customer-related focus. It involves CRMs, building up our churn desk, for instance, looking at customers. In other areas, it would cover areas like setting up a global procurement organization. So we've never -- previously, we had not had a global procurement organization and it was more regional. We have now stood up a global procurement organization. So I think that's giving you a color of the cross organization. It's not onetime. It's -- it's embedded in the SG&A numbers that you're looking at. There are areas on the R&D side as well. But again, those are more kind of baked into the business as opposed to onetime increasing our focus across the business. Both on the livestock business as well as companion animal, and we see opportunities there still. So I think it's an inflection point for our business. And as Glenn said, we'll see even more in 2027, and we hope to embed it within the business itself and to continue to see growth in the years to follow.

Our next question comes from the line of Ekaterina Knyazkova with JPMorgan.

Congratulations on the results. So first question is on the Zoetis Medicated Feed Additive business. You had the asset, I think, for several quarters now. Just where are we in terms of the integration process? And is there anything kind of that you guys are still working through anything kind of left for you to do. And as you've kind of been going through the process, are you seeing any areas where you can kind of maybe put additional resources behind the portfolio, both on the manufacturing side and the commercial side. And on second question is just around tariffs. Can you just remind us what you're investing in terms of the impact this year and maybe specifically talk about kind of the Brazil side, which just kind of given some of the headlines.

Thanks, Ekaterina. So I'll talk a little bit about the Zoetis integration, and Larry will join in as well and then from a [ tower ] perspective. So in terms of the Zoetis integration, where we had 8 months of results in this year and we're another 2 months in now at this point. And the integration is going very well. So all of the major system implementations are now complete, and we continue to progress in terms of doing the market trend positions and authorizations across the globe. We're pretty much operating independently for about 90% of the revenue. At this point in time, there are a number of markets that still need to transition over the next few months, but we expect to be operating fully independently by calendar Q4 this year. So everything is going very well and according to plan and all of the major integration items have been -- been complete or on schedule. I'll let Larry talk to a little bit of additional resources.

Yes. So again, we're seeing opportunities that the -- we have -- we're exposing our current products to new markets and new customers, particularly in areas like Asia, Western Europe and also this allowed us to entry into the US [indiscernible] cattle segment. So that has really helped us bring not only the acquired products, but also the combined basket of the type of solutions that we can bring to our customers. And so we are seeing some geographic as well as some market segment expansion opportunities.

And in terms of tariffs, Ekaterina. So our guidance does include tariffs as we know them today. Any significant changes, any changes in pharmaceutical tariffs or things of that nature are not fully embedded in the guidance. That being said, obviously, we have a guidance range, and we could probably accommodate some of that, but any major shifts have not been accounted for in the guidance.

Our next question comes from the line of Michael Ryskin with Bank of America.

Congrats on a strong end to fiscal year '25. Starting on the '26 guide, maybe just a follow-up on an earlier question. You did a $208 million from the Zoetis MFA contribution in 2026. So should we be assuming about $100 million in fiscal year '26 of inorganic contribution before terms organic from those first 4 months. And additionally, if you could say anything, Glenn, in terms of how much of the EBITDA and EPS -- adjusted EBITDA and adjusted EPS in 2026, is some of that lapping of the last 4 months before it turns organic -- just we can break that out.

Sure. Thanks for the question, Mike. As you said, we did $208 million in fiscal year '25. We initially guided to about $200 million. So we're pleased with the results that we saw in fiscal year '25 to the Zoetis MFA portfolio. Within that $208 million, as we talked about previously, the first few months, there was some destocking. So if you get a run rate out another 4 months would probably be a little higher than just half of the $208 million. When you look at the contribution from Zoetis to the EBITDA, as I mentioned, when you look at our current guidance range, it implies anywhere from, call it, $40 million to $50 million in incremental EBITDA next year. I would say at least half of that is coming from the contribution of having the full 12 months of Zoetis versus 8 months in fiscal year 2025. And the remainder comes from the growth in the legacy business and the contributions that we're seeing from Phibro Forward. .

Okay. That's really helpful. And then for a follow-up, I want to go back to last year, the Animal Health business. 7% overall -- I'm talking about the legacy business, to be clear. 7% total growth, 4 MFAs, 9, 13 Nutritional Specialties Vaccines. I think as you answered earlier to Erin's question, Glenn, those are really strong numbers, and it sounds like your assumptions for going forward are just a little bit more sort of back to historical trends for MFAs maybe a little bit more low single digits, maybe a little bit more high single digits, 10% for MFA and vaccines. So could you just talk about what worked so well for you in fiscal year '25 -- why were you able to execute so much better to hit that 7% in Animal Health this past year? Any specific drivers you could call out? Or just sort of what drove that outlet performance.

Yes. So I'll start just from a number perspective, and then I'll have Larry add in a little more strategic color, I think one of the things to look at from a number perspective, particularly when you look at the MFA growth that we saw this year is when you look at fiscal year 2024, the start to fiscal year 2024 was pretty subdued from an MFA perspective. So the comparators that we had this year helped enable stronger growth for the overall year, sort of seeing, as you mentioned, a little above what we typically see with the 4%. I think some of that was driven by a weaker comparator to last year, whereas going into fiscal year 2026, we had strong performance this year from the MFA business, which is why we expect slightly slower growth as we move into fiscal year 2026. Larry if you can add additional color.

Yes. In addition to the MFAs, we saw very continued strong sales growth and demand for our vaccines really across all of our geographic regions and also growth in our Nutritional Specialties products. That growth in both of those segments has come through some new product introductions in countries, but also penetration.

Our next question will come from the line of Navann Ty with BNP Paribas. .

Sorry if I missed it, but can you discuss the expected of the the Legacy MFA business? Or what are your expectation of the land market growth? And are you expecting the Legacy to company's market growth here? And also, have you seen any pull forward ahead of tariffs in international in the quarter?

You're a little hard to hear at the moment, but I'm going to try to interpret what I think the question is. So in terms of the expectation of the legacy MFA business, as we said, this year, we had strong growth 4%. We generally expect that market being a very mature market to grow sort of flat to low single digits, and that's the expectation that we have built into our guidance for fiscal year 2026. I think your questions around tariffs were there any pull forward ahead of tariffs into fiscal year 2025. And obviously, from an inventory perspective, a core opportunities for us to purchase inventory in advance of any potential tariffs. We took advantage of that where we could. But from our sales perspective, we don't believe that there was any advancement of sales and the sales that we had for Q4 fiscal year 2025 represent a good reflection of underlying demand.

And that will conclude our question-and-answer session. I'll hand the call back to Glenn for any final comments.

Thank you, Regina, and thank you, everyone, for listening on today's call. We really appreciate your time, attention and interest and support of Phibro Animal Health. I hope you all have a great day. Thank you.

And this concludes today's call. Thank you all for joining. You may now disconnect.